Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Fan W, Philip S, Toth PP, et al. Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: results from National Health and Nutrition Examination Survey (NHANES) 2007-2014. Am J Prevent Cardiol. 2020; epub ahead of print. https://www.sciencedirect.com/science/article/pii/S2666667720300878

Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S, Granowitz C, Navar AM. The Association between Triglycerides and Incident Cardiovascular Disease: What Is “Optimal”? Journal of Clinical Lipidology 2020;14:438-447.

https://www.lipidjournal.com/article/S1933-2874(20)30079-9/fulltext?dgcid=raven_jbs_etoc_email

Gitt AK. Prevalence Of Hypertriglyceridaemia In Statin Treated Very High-Risk Patients Who Might Benefit From Treatment With Icosapent Ethyl For Secondary Prevention In Clinical Practice–Results Of DYSIS. EMJ Cardiol. 2019;7:61-62.

https://emj.emg-health.com/wp-content/uploads/sites/2/2019/10/Icosapent-Ethyl-for-the-Prevention-of-Cardiovascular-Events.pdf
Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients

Nyandege A, Burudpakdee C, Philip S. Predictive modeling to assess predictors of treatment success and failure among combination statin therapy patients [abstract PRM20]. Value Health. 2014;17:A546.

copyright
© 2021, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
Spaces South Docklands
Block C
77 Sir John Rogerson's Quay
Dublin 2, D02 VK60
Investor Relations
AMARIN CORPORATION PLC C/O AMARIN PHARMA, INC.
440 ROUTE 22
BRIDGEWATER, NJ 08807
investor.relations@amarincorp.com
Fax:
+1 908 719 3012

Amarin Corporation